The present invention relates to the GPR119
receptor agonists: 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-dimethylbenzamide; -fluoro-4-(5-fluoro-6-(4-(3-(2-fluoro-propan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N-methylbenzamide; and 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)
benzamide, and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single pharmaceutical agent or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a
biguanide, an alpha-
glucosidase inhibitor, an
insulin analogue, a
sulfonylurea, an SGLT2 inhibitor, a meglitinide, a
thiazolidinedione, or an anti-diabetic
peptide analogue, in the treatment of for example, a disorder selected from: a GPR119-
receptor-
related disorder; a condition ameliorated by increasing
secretion of an
incretin; a condition ameliorated by increasing a blood
incretin level; a condition characterized by
low bone mass; a
neurological disorder; a metabolic-
related disorder; type 2 diabetes;
obesity; and complications related thereto.